Immune Checkpoint Blockade across the Cancer Care Continuum

Beth A. Helmink, Pierre Olivier Gaudreau, Jennifer A. Wargo

Research output: Contribution to journalShort surveypeer-review

23 Scopus citations

Abstract

Four studies recently reported in the New England Journal of Medicine highlight advances in treatment with immune checkpoint blockade across the cancer care continuum. These findings demonstrate efficacy of these agents in the treatment of early and late-stage disease, as monotherapy or in combination, and in addition to—or in place of—standard front-line therapy. Four studies recently reported in the New England Journal of Medicine highlight advances in treatment with immune checkpoint blockade across the cancer care continuum. These findings demonstrate efficacy of these agents in the treatment of early and late-stage disease, as monotherapy or in combination, and in addition to—or in place of—standard front-line therapy.

Original languageEnglish
Pages (from-to)1077-1080
Number of pages4
JournalImmunity
Volume48
Issue number6
DOIs
StatePublished - Jun 19 2018

Fingerprint

Dive into the research topics of 'Immune Checkpoint Blockade across the Cancer Care Continuum'. Together they form a unique fingerprint.

Cite this